LUT014

LUT014 is a topical inhibitor targeting BRAF that cannot pass through the blood-brain barrier. LUT014 inhibits BRAF kinase and abnormally activates the MAPK/ERK signaling pathway, promoting the proliferation of epidermal keratinocytes, repairing skin barrier damage caused by radiation damage, and alleviating inflammatory responses. LUT014 is independent of RAS signaling and accelerates the repair and regeneration of damaged skin cells. LUT014 can be used to study radiation dermatitis, especially skin damage caused by breast cancer radiotherapy[1][2][3].

Product Specifications

CAS Number

[2274819-46-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

ERK; p38 MAPK; Raf

Type

Reference compound

Related Pathways

MAPK/ERK Pathway; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/lut014.html

Purity

97.09

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

FC(F)(F)OC1=CC(NC2=NC=CC3=C2C=CC(C)=C3NC4=NC=CC=C4C5=C6N=CNC6=NC=N5)=CC=C1

Molecular Formula

C27H19F3N8O

Molecular Weight

528.49

Precautions

H302, H315, H319, H335

References & Citations

[1]Katz S, et al. A topical BRAF inhibitor (LUT-014) for treatment of radiodermatitis among women with breast cancer. JAAD Int. 2023 Dec 25;15:62-68.|[2]Wang PP, et al. BRAF Mutations in Colorectal Liver Metastases: Prognostic Implications and Potential Therapeutic Strategies. Cancers (Basel) . 2022 Aug 23;14 (17) :4067.|[3]Li Y, et al. Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies. Front Oncol. 2022 Feb 10;12:804212.